Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Kidney Function Tests”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 865 records · Page 48Linked to original sources
PubMed2004

Mycoplasma pneumoniae infection in a child after renal transplantation.

Although Mycoplasma pneumoniae infections are common among school children and young adults, they have been rarely reported in renal transplant recipients. Herein, we report an 8-yr-old boy who had M. pneumoniae infection 1 yr after transplantation and showed liver dysfunction during the course of the disease. In children who underwent renal transplantation and receive immunosuppressive treatment, we suggest that symptoms of a simple upper respiratory tract infection may precede M. pneumoniae disease with potentially serious extrapulmonary complications.

Acute Kidney Injury↗
PubMed1993

Metabolism of prednisone in kidney transplanted patients with necrosis of the femoral head.

Interindividual variation of the metabolism of prednisolone and of the susceptibility to glucocorticoids might be possible factors contributing to the development of osteonecrosis after renal allotransplantation. As this aspect has not been properly investigated previously, we compared, in the present study, the metabolism of total and free prednisolone in 6 renal allotransplanted patients who subsequently developed osteonecrosis of the femoral head and the metabolism of 6 matched controls, who did not develop osteonecrosis. There was no difference in age, bodyweight, total serum protein or albumin, or in liver or renal function. The baseline cortisol was 54 +/- 23 micrograms in patients with necrosis, and 102 +/- 53 micrograms/l in patients without necrosis (n.s.). Likewise there was no difference in the peak concentration of prednisolone (420 +/- 43 vs. 394 +/- 42 micrograms/l, n.s.), the bioavailability (0.57 +/- 0.09 vs. 0.61 +/- 0.05, n.s.) or in the apparent volume of distribution at steady state (Vdss, 0.37 +/- 0.09 vs. 0.37 +/- 0.04 l/kg, n.s.). The clearance of prednisolone in patients with osteonecrosis was 33% lower (0.79 +/- 0.11 vs. 1.18 +/- 0.13 ml/min./kg b.wt., P < 0.05) and t1/2 was correspondingly 33% longer (246 +/- 18 min. vs. 184 +/- 15 min., P < 0.05) than in patients without osteonecrosis. However, there was no difference in the apparent volume of distribution of free prednisolone (2.07 +/- 0.36 vs. 1.69 +/- 0.28 l/kg, n.s.), in the t1/2 (152 +/- 30 vs. 107 +/- 20 min., n.s.), or in the clearance (7.33 +/- 2.12 vs. 7.82 +/- 1.18 ml/min./kg) between the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Female↗
PubMed2000

Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.

Despite the availability of various lipid lowering drugs, the treatment of hyperlipidemia, one of the most important risk factors for morbidity and mortality after organ transplantation, remains a therapeutic challenge. We investigated the safety and efficacy of a new HMG-CoA reductase inhibitor, atorvastatin, in renal transplant patients whose serum lipids were insufficiently controlled by diet and treatment with other lipid lowering drugs. Twenty-four patients (14 males/10 females; mean age 51.2 +/- 2.3 years) were converted to low dose atorvastatin (10 mg/day) at a mean of 67.7 +/- 8.6 months after renal transplantation and prospectively followed for 3 months after initiation of the study drug. HDL, LDL, and total cholesterol, triglycerides, serum creatinine and CPK levels were evaluated pre (-3, -1, 0 months) and post conversion (+1, +3 months). In the eighteen patients who completed the study, low dose atorvastatin therapy led to a significant reduction in total cholesterol (304.6 +/- 13.2 vs. 247.6 +/- 12.0 mg/dl; p = 0.007) and LDL cholesterol (191.9 +/- 9.0 vs. 141.8 +/- 14.7 mg/dl; p < 0.0001) and a modest reduction in serum triglyceride levels at three months after conversion. We conclude that low dose atorvastatin (10 mg/day) can be successfully used and appears to be safe in the treatment of posttransplant hyperlipidemia. Its long-term effects on patient morbidity and mortality as well as graft survival should be investigated in larger and more prolonged prospective trials.

Adult↗
PubMed1989

[Progress in surgery and quality of life, quality of life after organ transplantation].

Kidney and liver transplantations are well established surgical procedures. During the past years survival rates have improved 3% of kidney transplantations have 1-year mortality. Subjective quality of life and professional rehabilitation are associated with the graft function parameters of successful therapy. Seventy-six percent of liver-transplanted patients consider their quality of life improved after the operation. 52% are able to return to work. Future efforts must focus on improving immunosuppression for specific tolerance and sensitizing the public to the problems of obtaining organs for transplantation.

Activities of Daily Living↗
PubMed1995

Treatment of recurrent cutaneous Leishmaniasis.

BACKGROUND: Cutaneous leishmaniasis is endemic in Iran. One of the clinical pictures of this disease is leishmaniasis recidivans (LR). Most of the drugs used for cutaneous leishmaniasis are ineffective in LR. METHODS AND PATIENTS: Twenty-five patients (13 women and 12 men), who had LR and whose disease had been proved by previous direct smears, were accepted for the study. The duration of disease in all patients was more than 2 years and they had previously been treated for their cutaneous leishmaniasis by different methods. All patients were treated with a combination of allopurinol (AL) (20 mg/kg/day for 30 days) and meglumine antimoniate (MA) (70 mg/kg/day for 15 days). Laboratory tests including hemograms, liver function, and kidney function tests, were done both at baseline and at the end of therapy. RESULTS: Twenty-four out of 25 patients (96%) responded well to treatment and after 1 year follow-up no relapse had occurred. The drugs were well tolerated by the patients producing no side effects nor any significant changes in laboratory values. CONCLUSIONS: A combination of AL and antimoniate is an effective method for the treatment of LR and for patients with cutaneous leishmaniasis who are resistant to the usual treatments.

Adolescent↗